Cargando…
Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015
BACKGROUND: In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States. OBJECTIVE: To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHO...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943633/ https://www.ncbi.nlm.nih.gov/pubmed/27410239 http://dx.doi.org/10.1371/journal.pntd.0004846 |
_version_ | 1782442627020357632 |
---|---|
author | Moro, Pedro L. Woo, Emily Jane Paul, Wendy Lewis, Paige Petersen, Brett W. Cano, Maria |
author_facet | Moro, Pedro L. Woo, Emily Jane Paul, Wendy Lewis, Paige Petersen, Brett W. Cano, Maria |
author_sort | Moro, Pedro L. |
collection | PubMed |
description | BACKGROUND: In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States. OBJECTIVE: To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS: We searched VAERS for US reports after HDCV among persons vaccinated from January 1, 1990–July 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category to each report using MedDRA system organ classes. Empirical Bayesian (EB) data mining was used to identify disproportional AE reporting after HDCV. RESULTS: VAERS received 1,611 reports after HDCV; 93 (5.8%) were serious. Among all reports, the three most common AEs included pyrexia (18.2%), headache (17.9%), and nausea (16.5%). Among serious reports, four deaths appeared to be unrelated to vaccination. CONCLUSIONS: This 25-year review of VAERS did not identify new or unexpected AEs after HDCV. The vast majority of AEs were non-serious. Injection site reactions, hypersensitivity reactions, and non-specific constitutional symptoms were most frequently reported, similar to findings in pre-licensure studies. |
format | Online Article Text |
id | pubmed-4943633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49436332016-08-01 Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 Moro, Pedro L. Woo, Emily Jane Paul, Wendy Lewis, Paige Petersen, Brett W. Cano, Maria PLoS Negl Trop Dis Research Article BACKGROUND: In 1980, human diploid cell vaccine (HDCV, Imovax Rabies, Sanofi Pasteur), was licensed for use in the United States. OBJECTIVE: To assess adverse events (AEs) after HDCV reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS: We searched VAERS for US reports after HDCV among persons vaccinated from January 1, 1990–July 31, 2015. Medical records were requested for reports classified as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis and Guillain-Barré syndrome (GBS). Physicians reviewed available information and assigned a primary clinical category to each report using MedDRA system organ classes. Empirical Bayesian (EB) data mining was used to identify disproportional AE reporting after HDCV. RESULTS: VAERS received 1,611 reports after HDCV; 93 (5.8%) were serious. Among all reports, the three most common AEs included pyrexia (18.2%), headache (17.9%), and nausea (16.5%). Among serious reports, four deaths appeared to be unrelated to vaccination. CONCLUSIONS: This 25-year review of VAERS did not identify new or unexpected AEs after HDCV. The vast majority of AEs were non-serious. Injection site reactions, hypersensitivity reactions, and non-specific constitutional symptoms were most frequently reported, similar to findings in pre-licensure studies. Public Library of Science 2016-07-13 /pmc/articles/PMC4943633/ /pubmed/27410239 http://dx.doi.org/10.1371/journal.pntd.0004846 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Moro, Pedro L. Woo, Emily Jane Paul, Wendy Lewis, Paige Petersen, Brett W. Cano, Maria Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 |
title | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 |
title_full | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 |
title_fullStr | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 |
title_full_unstemmed | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 |
title_short | Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 |
title_sort | post-marketing surveillance of human rabies diploid cell vaccine (imovax) in the vaccine adverse event reporting system (vaers) in the united states, 1990‒2015 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943633/ https://www.ncbi.nlm.nih.gov/pubmed/27410239 http://dx.doi.org/10.1371/journal.pntd.0004846 |
work_keys_str_mv | AT moropedrol postmarketingsurveillanceofhumanrabiesdiploidcellvaccineimovaxinthevaccineadverseeventreportingsystemvaersintheunitedstates19902015 AT wooemilyjane postmarketingsurveillanceofhumanrabiesdiploidcellvaccineimovaxinthevaccineadverseeventreportingsystemvaersintheunitedstates19902015 AT paulwendy postmarketingsurveillanceofhumanrabiesdiploidcellvaccineimovaxinthevaccineadverseeventreportingsystemvaersintheunitedstates19902015 AT lewispaige postmarketingsurveillanceofhumanrabiesdiploidcellvaccineimovaxinthevaccineadverseeventreportingsystemvaersintheunitedstates19902015 AT petersenbrettw postmarketingsurveillanceofhumanrabiesdiploidcellvaccineimovaxinthevaccineadverseeventreportingsystemvaersintheunitedstates19902015 AT canomaria postmarketingsurveillanceofhumanrabiesdiploidcellvaccineimovaxinthevaccineadverseeventreportingsystemvaersintheunitedstates19902015 |